- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 05.02. | GSK rides out vaccine sales weakness with cancer, HIV gains | ||
| 05.02. | Liva buys Momenta to bolster digital health platform | ||
| 05.02. | Novo rises on Wegovy sales leap, but warns of a slowdown | ||
| 05.02. | RFK Jr odds on for HHS role after Finance Committee vote | ||
| 04.02. | Algiax non-opioid drug works in chronic neuropathic pain | ||
| 04.02. | NHS trial puts AI for breast cancer screening under scrutiny | ||
| 04.02. | GH Research leaps on psychedelic data in depression | ||
| 04.02. | Pfizer builds on Braftovi bowel cancer OK with survival data | ||
| 04.02. | Trump tariffs 'would strain the pharma supply chain' | ||
| 03.02. | Bayer files finerenone in EU for heart failure | ||
| 03.02. | Report says AZ's UK plant decision is not just about funding | ||
| 03.02. | USAID site offline as Musk says it should be shut down | ||
| 31.01. | AstraZeneca abandons plan for £450m vaccine plant in UK | ||
| 31.01. | EMA experts will look again at Leqembi's safety data | ||
| 31.01. | Sickle cell gene therapy Casgevy finally cleared for NHS use | ||
| 31.01. | Two more biotechs, Metsera and Maze Therapeutics, cross IPO finish line | ||
| 31.01. | Vertex bags FDA okay for its non-opioid pain drug | ||
| 31.01. | Rad AI raises $60m, and other digital financings | ||
| 30.01. | Could an ECG spot people at risk of cognitive decline? | ||
| 30.01. | Medicare price negotiations 'will continue under Trump' | ||
| 30.01. | Dust mite allergy sufferers set for a new NHS treatment | ||
| 30.01. | Takeda CEO succession confirmed as Weber plans retirement | ||
| 30.01. | Vaccines dominate questioning of RFK Jr's first hearing | ||
| 29.01. | Troubled 23andMe is exploring a sale of the business | ||
| 29.01. | Ozempic is first GLP-1 drug FDA-approved for kidney disease |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
